First Financial Corp’s Vertex Pharmaceuticals VRTX Stock Holding History

First Financial Corp’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-29	Closed	-$12.1K	–	552
2024 Q1	$12.1K	Sell	29 -88	-75%	-$37.2K	0.01%	317
2023 Q4	$47.6K	Buy	117 +59	+102%	+$21.8K	0.02%	242
2023 Q3	$20.2K	Hold	58	–	–	0.01%	303
2023 Q2	$20.4K	Buy	58 +8	+16%	+$2.69K	0.01%	270
2023 Q1	$15.8K	Hold	50	–	–	0.01%	278
2022 Q4	$14.4K	Buy	50 +24	+92%	+$7.31K	0.01%	282
2022 Q3	$8K	Hold	26	–	–	0.01%	295
2022 Q2	$7K	Hold	26	–	–	﹤0.01%	299
2022 Q1	$7K	Hold	26	–	–	﹤0.01%	312
2021 Q4	$6K	Hold	26	–	–	﹤0.01%	322
2021 Q3	$5K	Hold	26	–	–	﹤0.01%	325
2021 Q2	$5K	Hold	26	–	–	﹤0.01%	328
2021 Q1	$6K	Hold	26	–	–	﹤0.01%	318
2020 Q4	$6K	Hold	26	–	–	﹤0.01%	326
2020 Q3	$7K	Hold	26	–	–	0.01%	321
2020 Q2	$8K	Hold	26	–	–	0.01%	291
2020 Q1	$6K	Hold	26	–	–	0.01%	303
2019 Q4	$6K	Hold	26	–	–	﹤0.01%	339
2019 Q3	$4K	Buy	+26	New	+$4.6K	﹤0.01%	357

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

First Financial Corp's VRTX Position: Q2 2024 in Review

First Financial Corp sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 29 shares — an estimated $12.1K sold.

First Financial Corp first reported a position in VRTX in Q3 2019 and held it in 19 quarters. The position peaked at $47.6K in Q4 2023. 1,550 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

First Financial Corp reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
First Financial Corp sold 29 Vertex Pharmaceuticals shares in Q2 2024, an estimated $12.1K.
First Financial Corp first reported a position in Vertex Pharmaceuticals in Q3 2019 and held it in 19 quarters.
First Financial Corp's Vertex Pharmaceuticals position peaked at $47.6K in Q4 2023.
1,550 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on First Financial Corp's 13F filing for Q2 2024, filed 11 Jul 2024.